All patients
HER2 positive
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
breast cancer - HER2-positive, neratinib based treatment vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results NALA, 2020 0.88 [0.72; 1.07]
NALA (brain metastases), 2020 0.90 [0.59; 1.38]
0.88 [0.74 ; 1.06 ] NALA, 2020, NALA (brain metastases), 2020 2 0% 722 moderate not evaluable iDFSdetailed results ExteNET, 2016 0.67 [0.50; 0.90]
0.67 [0.50 ; 0.90 ] ExteNET, 2016 1 0% 2,840 NA not evaluable progression or deaths (PFS)detailed results NALA, 2020 0.76 [0.63; 0.92]
NALA (brain metastases), 2020 0.66 [0.41; 1.06]
0.74 [0.62 ; 0.89 ] NALA, 2020, NALA (brain metastases), 2020 2 0% 722 moderate not evaluable RFS/DFSdetailed results ExteNET, 2016 0.63 [0.47; 0.85]
0.63 [0.47 ; 0.85 ] ExteNET, 2016 1 0% 2,840 NA not evaluable DORdetailed results NALA, 2020 0.50 [0.33; 0.75]
NALA (brain metastases), 2020 0.47 [0.12; 1.88]
0.50 [0.34 ; 0.73 ] NALA, 2020, NALA (brain metastases), 2020 2 0% 722 moderate not evaluable objective responses (ORR)detailed results NALA (brain metastases), 2020 1.02 [0.37; 2.80]
1.02 [0.37 ; 2.80 ] NALA (brain metastases), 2020 1 0% 74 NA not evaluable Anaemia AE (grade 3-4)detailed results NALA (brain metastases), 2020 0.48 [0.02; 14.79]
0.48 [0.02 ; 14.79 ] NALA (brain metastases), 2020 1 0% 99 NA not evaluable Asthenia AE (grade 3-4)detailed results NALA (brain metastases), 2020 0.31 [0.03; 3.12]
0.31 [0.03 ; 3.12 ] NALA (brain metastases), 2020 1 0% 99 NA not evaluable Back pain AE (grade 3-4)detailed results NALA (brain metastases), 2020 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] NALA (brain metastases), 2020 1 0% 99 NA not evaluable Constipation AE (grade 3-4)detailed results NALA (brain metastases), 2020 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] NALA (brain metastases), 2020 1 0% 99 NA not evaluable Decreased appetite AE (grade 3-4)detailed results NALA (brain metastases), 2020 0.98 [0.06; 16.11]
0.98 [0.06 ; 16.11 ] NALA (brain metastases), 2020 1 0% 99 NA not evaluable Diarrhoea AE (grade 3-4)detailed results NALA (brain metastases), 2020 2.48 [0.79; 7.77]
2.48 [0.79 ; 7.77 ] NALA (brain metastases), 2020 1 0% 99 NA not evaluable Fatigue AE (grade 3-4)detailed results NALA (brain metastases), 2020 0.98 [0.13; 7.24]
0.98 [0.13 ; 7.24 ] NALA (brain metastases), 2020 1 0% 99 NA not evaluable Headache AE (grade 3-4)detailed results NALA (brain metastases), 2020 0.98 [0.02; 50.38]
0.98 [0.02 ; 50.38 ] NALA (brain metastases), 2020 1 0% 99 NA not evaluable Nausea AE (grade 3-4)detailed results NALA (brain metastases), 2020 0.64 [0.10; 4.00]
0.64 [0.10 ; 4.00 ] NALA (brain metastases), 2020 1 0% 99 NA not evaluable Palmar–plantar erythrodysesthesia syndrome AE (grade 3-4)detailed results NALA (brain metastases), 2020 0.98 [0.29; 3.27]
0.98 [0.29 ; 3.27 ] NALA (brain metastases), 2020 1 0% 99 NA not evaluable Pyrexia AE (grade 3-4)detailed results NALA (brain metastases), 2020 0.48 [0.02; 14.79]
0.48 [0.02 ; 14.79 ] NALA (brain metastases), 2020 1 0% 99 NA not evaluable Rash AE (grade 3-4)detailed results NALA (brain metastases), 2020 0.48 [0.02; 14.79]
0.48 [0.02 ; 14.79 ] NALA (brain metastases), 2020 1 0% 99 NA not evaluable Stomatitis AE (grade 3-4)detailed results NALA (brain metastases), 2020 0.48 [0.02; 14.79]
0.48 [0.02 ; 14.79 ] NALA (brain metastases), 2020 1 0% 99 NA not evaluable Vomiting AE (grade 3-4)detailed results NALA (brain metastases), 2020 0.98 [0.06; 16.11]
0.98 [0.06 ; 16.11 ] NALA (brain metastases), 2020 1 0% 99 NA not evaluable Weight decreased AE (grade 3-4)detailed results NALA (brain metastases), 2020 0.98 [0.06; 16.11]
0.98 [0.06 ; 16.11 ] NALA (brain metastases), 2020 1 0% 99 NA not evaluable 0.2 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-05-20 22:28 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 336,147,145,355,337,146,317
- treatments: 1313,498,1314
